Sunday, 8 November 2015

FDA approves new treatment for HIV - Genvoya



The U.S. Food and Drug Administration on Thursday approved Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older.

Genvoya is an effective, once daily complete regimen for patients with HIV-1 infection.

 It's been approved for use in HIV-infected adults and children ages 12 years and older weighing at least 35 kilograms (77 pounds) who have never taken HIV therapy (treatment-na├»ve) and HIV-infected adults whose HIV-1 virus is currently suppressed. While Genvoya is not recommended for patients with severe renal impairment, those with moderate renal impairment can take Genvoya.

No comments:

Post a Comment

Aisha Buhari urges doctors to check abuses, exorbitant charges

A post shared by HealthThenMore (HTM) Lifestyle (@htm_lifestyle) on Apr 17, 2018 at 12:12am PDT The wife of the President, Mrs...